ramosetron vs. ondansetron after craniotomy

Comparison of ramosetron with ondansetron for the prophylaxis of PONV after craniotomy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0000320

Enrollment

160

Registered

2012-01-11

Start date

2012-01-25

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : At the end of surgery, intravenous ondansetron 4mg, ondansetron 8mg, or ramosetron 0.3 mg (identical syringe with 4 ml solution) administered to the patients.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) patients scheduled to be performed craniotomy 2) aged 19-65 3) American Society of Anesthesiologist class I-II 4) informed consent

Exclusion criteria

Exclusion criteria: 1) Scheduled to be sedated after craniotomy, or unable to communicate after surgery 2) Glasgo Coma Scale 1.6 mg/dl) , or hepatic insufficiency (liver enzymes more than 2 times normal value)

Design outcomes

Primary

Measure	Time frame
nausea;nausea numerical rating scale (NRS);retching;vomitting;need of antiemetics	—

Secondary

Measure	Time frame
patient controlled analgesia (PCA) consumption;itching	—

Countries

Korea, Republic of

Contacts

Public ContactJung-Hee Ryu

Seoul National University Bundang Hospital

jinaryu@lycos.co.kr+82-31-787-7497

Outcome results